Detailed Information
Cited 0 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Exploratory biomarker analysis from a phase II, multicenter, randomized trial of eribulin plus gemcitabine(EG) versus paclitaxel plus gemcitabine(PG) as first-line chemotherapy for human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer(MBC): Korean cancer study group trial (KCSG BR13-11)
- Authors
- Kim, JY[Kim, J-Y]; Lee, EJ[Lee, E. J.]; Park, KH[Park, K. H.]; Im, SA[Im, S-A]; Kim, SB[Kim, S-B]; Sohn, SH[Sohn, S. H.]; Lee, KS[Lee, K. S.]; Chae, YS[Chae, Y. S.]; Lee, KH[Lee, K. H.]; Kim, JH[Kim, J. H.]; Im, YH[Im, Y-H]; Kim, TY[Kim, T-Y]; Lee, KH[Lee, K-H]; Ahn, JH[Ahn, J-H]; Kim, GM[Kim, G. M.]; Park, IH[Park, I. H.]; Lee, SJ[Lee, S. J.]; Han, HS[Han, H. S.]; Kim, SH[Kim, S. H.]; Jung, KH[Jung, K. H.]; Park, YH[Park, Y. H.]
- Issue Date
- Feb-2019
- Publisher
- AMER ASSOC CANCER RESEARCH
- Citation
- CANCER RESEARCH, v.79, no.4
- Indexed
- SCIE
SCOPUS
- Journal Title
- CANCER RESEARCH
- Volume
- 79
- Number
- 4
- ISSN
- 0008-5472
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.